N^im-trityl-L-histidine hydrochloride | 32946-53-5

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 组氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: N^im-trityl-L-histidine hydrochloride
• 英文别名: (2S)-2-amino-3-(1-tritylimidazol-4-yl)propanoic acid;hydrochloride
• CAS: 32946-53-5
• 化学式: C₂₅H₂₃N₃O₂*ClH
• 分子量: 433.937
• InChiKey: RAVIREPCGXEBQP-BQAIUKQQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  81.1
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N^im-trityl-L-histidine hydrochloride 在 ammonium hydroxide 、 potassium carbonate 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.55h， 生成 N-[(苯甲氧基)羰基]-1-(三苯基甲基)-L-组氨酸
  参考文献：
  名称：

  Improved methods of obtaining Nim-trityl-substituted histidine derivatives

  摘要：

  DOI：

  10.1007/bf00580461
• 作为产物：
  描述：

  N^α,N^im-ditritylhistidine 在 盐酸 作用下， 以 丙酮 为溶剂， 生成 N^im-trityl-L-histidine hydrochloride
  参考文献：
  名称：

  Improved methods of obtaining Nim-trityl-substituted histidine derivatives

  摘要：

  DOI：

  10.1007/bf00580461

文献信息

• 3-(Imidazolyl)-2-aminopropanoic acids
  申请人：Pfizer Inc.

  公开号：US20030191107A1

  公开（公告）日：2003-10-09

  Compounds according to formula (I) wherein n is 1-4, R 1 is optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition. 1

  根据公式(I)，其中n为1-4，R1是可选取代的C1-6烷基、C2-6烯基或C2-6炔基、杂环、芳香杂环、芳基或氢，而R2、R3、R4、R5、R6、R7和R8各自独立选择自氢和可选取代的C1-6烷基的化合物是新颖的。它们在治疗血栓症和与纤维蛋白沉积相关的其他病理情况中非常有用。
• 3-(imidazolyl)-2-aminopropanoic acids
  申请人：Pfizer Inc

  公开号：US20040192668A1

  公开（公告）日：2004-09-30

  Compounds according to formula (I) wherein n is 1-4, R 1 is optionally substituted C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition. 1

  公式（I）中的化合物，其中n为1-4，R1为可选取代的C1-6烷基，C2-6烯基或C2-6炔基，杂环，芳香杂环，芳基或氢，而R2，R3，R4，R5，R6，R7和R8各自独立地选自氢和可选取代的C1-6烷基，是新颖的。它们在治疗血栓性疾病和与纤维蛋白沉积有关的其他病理情况中有用。
• Antiviral compounds
  申请人：HAPLOGEN GMBH

  公开号：US11091428B2

  公开（公告）日：2021-08-17

  The present invention relates to novel compounds of general formula (I) wherein the groups X, and R1 to R4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.

  本发明涉及通式(I)的新型化合物（其中基团X和R1至R4的含义见说明书和权利要求书）、制备这些化合物的工艺及其用于治疗、预防或改善病毒感染的用途，以及用于治疗、预防或改善与PLA2G16有关的疾病的用途。
• 3-(IMIDAZOLYL)-2-AMINOPROPANOIC ACIDS FOR USE AS TAFI-A INHIBITORS FOR THE TREATMENT OF THROMBOTIC DISEASES
  申请人：Pfizer Limited

  公开号：EP1467732A1

  公开（公告）日：2004-10-20
• ANTIVIRAL COMPOUNDS
  申请人：HAPLOGEN GMBH

  公开号：US20190225575A1

  公开（公告）日：2019-07-25

  The present invention relates to novel compounds of general formula (I) wherein the groups X, and R 1 to R 4 have the meanings given in the description and claims, process for preparing these compounds and their use as for treating, preventing or ameliorating viral infections and their use for treating, preventing or ameliorating diseases which are associated with PLA2G16.